Exploitation of Bruton’s kinase (BTK) pathway in malignant diseases

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorNawaiseh, Mohammad Yahya Suleiman
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentMegyeri, Attila
dc.contributor.opponentdeptKenézy Kórház, Aneszteziológiai és Intenziv Therápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2022-01-19T11:06:48Z
dc.date.available2022-01-19T11:06:48Z
dc.date.created2021-06-11
dc.description.abstractThe important role of BTK pathway in many processes associated with malignancies has been undoubtedly proven. BTK was linked to many B cell malignancies. Studies and trials attempting to find ways to exploit the BTK in B cell malignancies lead to the approval of many BTK inhibitors like Ibrutinib and Acalabrutinib in many B cell malignancies. An important group of patients benefiting from these agents were the relapsed/ refractory group (R/R) amongst other indications for various malignancies including WM, CLL/SLL, MCL and MZL. Although BTK inhibitors have revolutionized the treatment of many malignant diseases, toxicities and resistance cause decreased benefit/risk ratio and may lead to discontinuation of therapy. Toxicities have ranged from minimal that could be managed in different ways to life threatening that requires discontinuation. As a result, developing BTK inhibitor with a better safety profile have become one of the corner stones in this field along with investigating other malignancies that can benefit from this therapy option.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent40hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/328022
dc.language.isoenhu_HU
dc.subjectBTK pathway in malignant diseaseshu_HU
dc.subjectBruton’s kinase
dc.subjectBTK inhibitors
dc.subject.dspaceDEENK Témalista::Orvostudomány::Gyógyszerésztudományhu_HU
dc.titleExploitation of Bruton’s kinase (BTK) pathway in malignant diseaseshu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)